Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Sascha Troschke-Meurer"'
Autor:
Thomas Freitag, Philipp Kaps, Justus Ramtke, Sarah Bertels, Emily Zunke, Björn Schneider, Anne-Sophie Becker, Dirk Koczan, Daniel Dubinski, Thomas M. Freiman, Felix Wittig, Burkhard Hinz, Mike-Andrew Westhoff, Hannah Strobel, Franziska Meiners, Daniel Wolter, Nadja Engel, Sascha Troschke-Meurer, Wendy Bergmann-Ewert, Susanne Staehlke, Annabell Wolff, Florian Gessler, Christian Junghanss, Claudia Maletzki
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-17 (2024)
Abstract Here, we show that combined use of the EZH2 inhibitor GSK126 and the CDK4/6 inhibitor abemaciclib synergistically enhances antitumoral effects in preclinical GBM models. Dual blockade led to HIF1α upregulation and CalR translocation, accomp
Externí odkaz:
https://doaj.org/article/48c31a82a0d54c5ea79c6f99d70e3d61
Autor:
Christin Riess, Katharina del Moral, Adina Fiebig, Philipp Kaps, Charlotte Linke, Burkhard Hinz, Anne Rupprecht, Marcus Frank, Tomas Fiedler, Dirk Koczan, Sascha Troschke-Meurer, Holger N. Lode, Nadja Engel, Thomas Freitag, Carl Friedrich Classen, Claudia Maletzki
Publikováno v:
Cell Death and Disease, Vol 13, Iss 6, Pp 1-14 (2022)
The complex effects of combined CDki/SPyADI application on arginine-auxotrophic glioblastoma multiforme cells. CDki/SPyADI combination therapy impairs cell proliferation, invasiveness, gene expression, induces mitochondrial impairment, and vacuole fo
Externí odkaz:
https://doaj.org/article/e4a237d57e9d4704bd9c0f69a431ba27
Autor:
Hannes Forkel, Piotr Grabarczyk, Maren Depke, Sascha Troschke-Meurer, Stefan Simm, Elke Hammer, Stephan Michalik, Christian Hentschker, Björn Corleis, Lucie Loyal, Maxi Zumpe, Nikolai Siebert, Anca Dorhoi, Andreas Thiel, Holger Lode, Uwe Völker, Christian A. Schmidt
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
ABSTRACTBCL11B, an essential transcription factor for thymopoiesis, regulates also vital processes in post-thymic lymphocytes. Increased expression of BCL11B was recently correlated with the maturation of NK cells, whereas reduced BCL11B levels were
Externí odkaz:
https://doaj.org/article/38c9a1f16c6741208dbf26b7a38a18f3
Autor:
Christian Martin Seitz, Tim Flaadt, Markus Mezger, Anne-Marie Lang, Sebastian Michaelis, Marie Katz, Desireé Syring, Alexander Joechner, Armin Rabsteyn, Nikolai Siebert, Sascha Troschke-Meurer, Maxi Zumpe, Holger N. Lode, Sile F. Yang, Daniel Atar, Anna-Sophia Mast, Sophia Scheuermann, Florian Heubach, Rupert Handgretinger, Peter Lang, Patrick Schlegel
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Haploidentical stem cell transplantation (haplo SCT) in Stage IV neuroblastoma relapsed patients has been proven efficacious, while immunotherapy utilizing the anti-GD2 antibody dinutuximab beta has become a standard treatment for neuroblastoma. The
Externí odkaz:
https://doaj.org/article/3db6c45432c649c5ab96cdd2344832c5
Autor:
Filiz Cicek, Sascha Troschke-Meurer, Kiraz Ceylan, Luciana J. Jahns, Maxi Zumpe, Nikolai Siebert, Karoline Ehlert, Holger N. Lode
Publikováno v:
Frontiers in Pediatrics, Vol 8 (2020)
Patients with high-risk neuroblastoma treated with continuous long-term infusion of anti-GD2 antibody dinutuximab beta (DB) in combination with IL-2 show an acceptable safety profile. Here, we compared treatment tolerance with and without IL-2. Ninet
Externí odkaz:
https://doaj.org/article/d64eecd9b1d8462d88e41db19379f01a
Autor:
Nikolai Siebert, Maxi Zumpe, Leon von Lojewski, Sascha Troschke-Meurer, Madlen Marx, Holger N. Lode
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Neuroblastoma (NB) still remains a major challenge in pediatric oncology. We recently showed CD11b+-dependent upregulation of the PD-1/PD-L1 checkpoint on NB cells treated with the chimeric anti-GD2 antibody (Ab) ch14.18/CHO. Here, we report effects
Externí odkaz:
https://doaj.org/article/c4972936abb24748a9d0e6ea4e1fdc35
Autor:
Sascha Troschke-Meurer, Nikolai Siebert, Madlen Marx, Maxi Zumpe, Karoline Ehlert, Oliver Mutschlechner, Hans Loibner, Ruth Ladenstein, Holger N. Lode
Publikováno v:
OncoImmunology, Vol 8, Iss 12 (2019)
Immunotherapy with the anti-GD2 antibody (Ab) ch14.18/CHO in combination with interleukin 2 (IL-2) has improved survival of high-risk neuroblastoma (NB) patients. Here, we report immunotherapy-related effects on circulating NK cells, regulatory T cel
Externí odkaz:
https://doaj.org/article/1add2821f0c7408d98e60669870206e0
Publikováno v:
PLoS ONE, Vol 13, Iss 11, p e0207320 (2018)
Long-term survival of high-risk neuroblastoma (NB) patients still remains under 50%. Here, we report the generation, in vitro characterization and anti-tumor effectivity of a new bicistronic xenogenic DNA vaccine encoding tyrosine hydroxylase (TH) th
Externí odkaz:
https://doaj.org/article/771ff7bb02fe407bac8835a05403efbe
Publikováno v:
OncoImmunology, Vol 6, Iss 10 (2017)
Immunotherapy with anti-GD2 antibody (Ab) ch14.18/CHO is effective for treatment of high-risk neuroblastoma (NB) patients and is mainly based on GD2-specific Ab-dependent cellular cytotoxicity (ADCC). Strategies to further enhance the efficacy are im
Externí odkaz:
https://doaj.org/article/80b8c37353e54ee095987490da130f1e
Autor:
Wieczorek, Holger N. Lode, Ruth Ladenstein, Sascha Troschke-Meurer, Linda Struppe, Nikolai Siebert, Maxi Zumpe, Karoline Ehlert, Stefanie Huber, Evgenia Glogova, Patrick Hundsdoerfer, Angelika Eggert, Anna Zaniewska-Tekieli, Walentyna Balwierz, Aleksandra
Publikováno v:
Cancers; Volume 15; Issue 13; Pages: 3364
The anti-disialoganglioside (GD2) monoclonal antibody dinutuximab beta is approved for the maintenance treatment of high-risk neuroblastoma. Dinutuximab beta combined with different chemotherapy regimens is being investigated in various clinical sett
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::9f56d6fe47ef7c0b475a4af7ee4fa43c